Abstract
The applications of surface plasmon resonance (SPR) and biosensor technology for biospecific interaction analysis (BIA) of molecular interactions between transcription modifiers and target biomolecules is here described for the identification of possible candidates for drug research and development in antitumor and antiviral therapy. SPR-based BIA offers many advantages with respect to most of the other available methodologies to study biomolecular interactions. It should be underlined that (a) most commercially available biosensors are fully automated instruments; (b) no labelling is required; (c) a large variety of activated sensor chips are commercially available allowing the immobilization of either proteins or target DNA or RNA; (d) the amount of both ligand and analyte needed to obtain informative results is low; (e) the assay is rapid and (f) the sensor chip could be re-used many times, leading to low running costs, with the only limitation of verifying the stability of the immobilized ligand. Approaches employing SPR-based BIA were described for the development of (a) triple-helix forming oligonucleotides (TFO) and peptide nucleic acids (PNAs), (b) DNA-binding drugs, (c) decoy molecules and (d) PNAs able to perform strand invasion. All these biomolecules are of great interest for the development of transcription modifiers. Since alteration of the expression of transcription factors is involved in tumor cell growth and metastasis, SPR-based BIA appears to be a methodology of great impact in the design and development of anti-cancer agents.
Current Medicinal Chemistry - Anti-Cancer Agents
Title: Biospecific Interaction Analysis (BIA) as a Tool for the Design and Development of Gene Transcription Modifiers
Volume: 1 Issue: 3
Author(s): Roberto Gambari
Affiliation:
Abstract: The applications of surface plasmon resonance (SPR) and biosensor technology for biospecific interaction analysis (BIA) of molecular interactions between transcription modifiers and target biomolecules is here described for the identification of possible candidates for drug research and development in antitumor and antiviral therapy. SPR-based BIA offers many advantages with respect to most of the other available methodologies to study biomolecular interactions. It should be underlined that (a) most commercially available biosensors are fully automated instruments; (b) no labelling is required; (c) a large variety of activated sensor chips are commercially available allowing the immobilization of either proteins or target DNA or RNA; (d) the amount of both ligand and analyte needed to obtain informative results is low; (e) the assay is rapid and (f) the sensor chip could be re-used many times, leading to low running costs, with the only limitation of verifying the stability of the immobilized ligand. Approaches employing SPR-based BIA were described for the development of (a) triple-helix forming oligonucleotides (TFO) and peptide nucleic acids (PNAs), (b) DNA-binding drugs, (c) decoy molecules and (d) PNAs able to perform strand invasion. All these biomolecules are of great interest for the development of transcription modifiers. Since alteration of the expression of transcription factors is involved in tumor cell growth and metastasis, SPR-based BIA appears to be a methodology of great impact in the design and development of anti-cancer agents.
Export Options
About this article
Cite this article as:
Gambari Roberto, Biospecific Interaction Analysis (BIA) as a Tool for the Design and Development of Gene Transcription Modifiers, Current Medicinal Chemistry - Anti-Cancer Agents 2001; 1 (3) . https://dx.doi.org/10.2174/1568011013354525
DOI https://dx.doi.org/10.2174/1568011013354525 |
Print ISSN 1568-0118 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5968 |
Related Articles
-
The Current Status of Antimalarial Drug Research with Special Reference to Application of QSAR Models
Combinatorial Chemistry & High Throughput Screening Recent Advances in Physical Approaches for Transdermal Penetration Enhancement
Current Drug Therapy The Potential Role of Claudins in Regulation of Metastasis and Development of Drug Resistance in Breast Cancer
Clinical Cancer Drugs Recent Advances in Immunotherapy for Allergic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery 6,7-Dimethoxyquinazolines as Potential Cytotoxic Agents: Synthesis and in vitro Activity
Letters in Drug Design & Discovery Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Current Drug Targets Synthesis, Biological and Computational Evaluation of Novel 2,3-dihydro-2-aryl-4-(4- isobutylphenyl)-1,5-benzothiazepine Derivatives as Anticancer and Anti-EGFR Tyrosine Kinase Agents
Anti-Cancer Agents in Medicinal Chemistry Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science The Identification of a Novel Unsymmetrical Azine as an Apoptosis Inducer in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Applications of Stripping Voltammetry at Carbon Paste and Chemically Modified Carbon Paste Electrodes to Pharmaceutical Analysis
Current Pharmaceutical Analysis Carbon Nanotubes as an Advanced Drug and Gene Delivery Nanosystem
Current Nanoscience In Vitro Cytochrome P450 Inhibition and Induction
Current Drug Metabolism Recent Progress on the Applications of Multifunctional Glyconanoparticles
Current Pharmaceutical Design Fatty Acid-Mediated Inhibition of Metal Binding to the Multi-Metal Site on Serum Albumin: Implications for Cardiovascular Disease
Current Topics in Medicinal Chemistry Synthesis of N-glycosylated Dihydropyrimidones – A Novel Approach Using Epoxy Sugar
Letters in Organic Chemistry Future of Protease Activity Assays
Current Pharmaceutical Design Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Drug Excipients
Current Medicinal Chemistry The Role of Binding Kinetics in GPCR Drug Discovery
Current Topics in Medicinal Chemistry Synthesis, Antifungal Activity and Carbonic Anhydrase Inhibitory Properties of Cu (II) Bis (3, 4 Dimethoxybenzoate) Bis (Nicotinamide) Dihydrate
Current Enzyme Inhibition